Clinical trial
Safety and Pharmacokinetics of IGSC 20% in Subjects With Primary…
NCT02604810 · Grifols Therapeutics LLC, Industry · Completed
Key facts
| NCT number | NCT02604810 |
|---|---|
| Title | Safety and Pharmacokinetics of IGSC 20% in Subjects With Primary Immunodeficiency |
| Official title | An Open-label, Multi-center Study to Evaluate the Safety and Pharmacokinetics of IGSC 20% Administered for 6 Months in Subjects With Primary Immunodeficiency |
| Lead sponsor | Grifols Therapeutics LLC, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Primary Immunodeficiency |
| Intervention type | Biological |
| Interventions | IGIV-C 10%, IGSC 20% |
| Enrollment | 53 |
| Start date | Jan 1, 2016 |
| Primary completion | Sep 1, 2017 |
| Completion | Dec 1, 2017 |
| First posted | Nov 13, 2015 |
| Last update posted | Oct 4, 2019 |
| Countries | Canada, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: